Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 31 to 40 of 2245 total matches.

Mirabegron (Myrbetriq) for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • Feb 18, 2013  (Issue 1410)
to be approved for any indication in the US. Mirabegron has been marketed in Japan since 2011. Table 1. Some ...
Mirabegron (mir a beg’ ron; Myrbetriq [meer BEH trick] – Astellas), a beta-3 adrenergic agonist, has been approved by the FDA for the treatment of overactive bladder. It is the first beta-3 adrenergic agonist to be approved for any indication in the US. Mirabegron has been marketed in Japan since 2011. OnabotulinumtoxinA (Botox) was also recently approved by the FDA for treatment of overactive bladder and will be reviewed in a future issue.
Med Lett Drugs Ther. 2013 Feb 18;55(1410):13-5 | Show Introduction Hide Introduction

Expanded Table: Some Vaccines Recommended for Use in Adults (online only)

   
The Medical Letter on Drugs and Therapeutics • May 07, 2018  (Issue 1546)
, Diphtheria (Td) Tetanus and Diptheria Toxoids Tenivac (SanofiPasteur) 0.5 mL IM 3 doses (0, 1, and 6-12 ...
View the Expanded Table: Some Vaccines Recommended for Use in Adults
Med Lett Drugs Ther. 2018 May 7;60(1546):e82-5 | Show Introduction Hide Introduction

Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C

   
The Medical Letter on Drugs and Therapeutics • Aug 15, 2016  (Issue 1501)
— The prevalence of HCV genotypes in the US is about 75% for genotype 1, 20-25% for genotypes 2 and 3, and ...
The FDA has approved Epclusa (Gilead), a fixed-dose combination of sofosbuvir (Sovaldi) and velpatasvir, a new direct-acting antiviral agent, for oral treatment of chronic hepatitis C virus (HCV) infection. Epclusa is the first oral combination to be approved for treatment of all six major HCV genotypes.
Med Lett Drugs Ther. 2016 Aug 15;58(1501):107-8 | Show Introduction Hide Introduction

Tirzepatide (Mounjaro) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022  (Issue 1654)
-like peptide-1 (GLP-1) receptors, to improve glycemic control in adults with type 2 diabetes ...
The FDA has approved tirzepatide (Mounjaro – Lilly), a peptide hormone with activity at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, to improve glycemic control in adults with type 2 diabetes. Tirzepatide, which is injected subcutaneously once weekly, is the first dual GIP/GLP-1 receptor agonist to become available in the US. Selective GIP receptor agonists are not available in the US; GLP-1 receptor agonists have been available for years.
Med Lett Drugs Ther. 2022 Jul 11;64(1654):105-7 | Show Introduction Hide Introduction

Two New Drugs for HIV Infection

   
The Medical Letter on Drugs and Therapeutics • Jan 14, 2008  (Issue 1277)
class of oral HIV drugs called HIV-1 integrase strand transfer inhibitors (InSTI), has received ...
Raltegravir (Isentress - Merck), the first in a new class of oral HIV drugs called HIV-1 integrase strand transfer inhibitors (InSTI), has received accelerated FDA approval for use in combination therapy for treatment-experienced adults infected with HIV-1 strains resistant to multiple antiretroviral agents.

Maraviroc (Selzentry - Pfizer), the first CCR5 (CC chemokine receptor 5) antagonist has received the same FDA approval but is restricted to use in adults with CCR5-tropic HIV-1 ("R5 virus"). A commercial assay is available for R5 tropism.
Med Lett Drugs Ther. 2008 Jan 14;50(1277):2-4 | Show Introduction Hide Introduction

New Drugs for Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • May 01, 2000  (Issue 1077)
Street, New Rochelle, N.Y. 10801 • A Nonprofit Publication Vol. 42 (W1077B) May 1, 2000 REPRODUCED ...
Ophthalmic formulations of ketotifen fumarate (Zaditor), pemirolast potassium (Alamast) and nedocromil sodium (Alocril) have recently been approved by the FDA for use in adults and children with itching of the eyes due to allergic conjunctivitis.
Med Lett Drugs Ther. 2000 May 1;42(1077):39-40 | Show Introduction Hide Introduction

In Brief: Higher-Dose Semaglutide (Ozempic) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • May 16, 2022  (Issue 1650)
peptide-1 (GLP-1) receptor agonist semaglutide (Ozempic) for treatment of type 2 diabetes in adults ...
The FDA has approved a higher-dose injectable formulation of the long-acting glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Ozempic) for treatment of type 2 diabetes in adults. A single SC injection of the new 8 mg/3 mL formulation delivers 2 mg of semaglutide.
Med Lett Drugs Ther. 2022 May 16;64(1650):79 | Show Introduction Hide Introduction

In Brief: OTC Alcaftadine (Lastacaft Once Daily Relief) for Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • May 16, 2022  (Issue 1650)
antihistamine to be approved for over-the counter (OTC) use (see Table 1). Ophthalmic H1-antihistamines ...
The ophthalmic H1-antihistamine alcaftadine 0.25%, which has been available by prescription since 2011 for use in patients with allergic conjunctivitis, is now available without a prescription as Lastacaft Once Daily Relief (Allergan) for temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair, and dander in adults and children ≥2 years old. It is the third ophthalmic antihistamine to be approved for over-the-counter (OTC) use (see Table 1).
Med Lett Drugs Ther. 2022 May 16;64(1650):78 | Show Introduction Hide Introduction

Brimonidine - An Alpha2-Agonist for Glaucoma

   
The Medical Letter on Drugs and Therapeutics • Jun 06, 1997  (Issue 1002)
Cost 1 Adrenergic agonist Dipivefrin hydrochloride 0.1% 1 drop b.i.d. generic price $ 20.25 ...
Brimonidine tartrate 0.2% ophthalmic solution (Alphagan - Allergan), a selective alpha2-adrenergic agonist, has been approved by the US Food and Drug Administration (FDA) for treatment of increased intraocular pressure due to open-angle glaucoma or ocular hypertension and for its prevention in patients undergoing argon laser trabeculoplasty.
Med Lett Drugs Ther. 1997 Jun 6;39(1002):54-5 | Show Introduction Hide Introduction

In Brief: Nitisinone Oral Suspension (Orfadin) for Hereditary Tyrosinemia (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 10, 2016  (Issue 1505)
) for treatment of hereditary tyrosinemia type 1 (HT-1). Orfadin has been available in a capsule formulation ...
The FDA has approved an oral suspension formulation of nitisinone (Orfadin – Sobi) for treatment of hereditary tyrosinemia type 1 (HT-1). Orfadin has been available in a capsule formulation in Canada since 1994 and in the US since 2002.HT-1 is an autosomal recessive genetic disorder (estimated birth prevalence: 1:100,000) caused by mutations in the gene responsible for formation of fumarylacetoacetate hydrolase (FAH), which catalyzes the last step in tyrosine metabolism. FAH deficiency results in accumulation of upstream toxic metabolites, causing liver and kidney failure and developmental...
Med Lett Drugs Ther. 2016 Oct 10;58(1505):e132 | Show Introduction Hide Introduction